This text is a result of machine translation.
Russian finance minister says West creates artificial obstacles for Russia to repay public debt
The maximum payment limit of employee medical insurance in Shanghai in 2022 was raised to 590000 yuan
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Sanlian board Shenma power: the company's gross profit margin declined to a certain extent in the first quarter
The private placement market is full of chaos, and the regulators' sword is intended to support the good and limit the bad
Cro plate fell, and Wuxi apptec fell nearly 10%
The trading limit of AVIC electronics and AVIC electromechanical resumed
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
Luoxin pharmaceutical: fosapitam for injection and meglumine have obtained the drug registration certificate
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
The port sector continued to strengthen and Guangzhou port rose by the daily limit
Fosun Pharmaceutical: the new tablet production line of the holding subsidiary passed the GMP compliance inspection
Xuelang environment: affected by the epidemic situation, the subsidiary temporarily stopped production and resumed production
Fosun Pharmaceutical: the holding subsidiary started the phase II clinical study on the treatment of fs-1502 for non-small cell lung cancer
On May 11, Ping An of China spent 299 million yuan to buy back 6.6972 million a shares
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
Charging Infrastructure on Government Support: A Brighter Future?
Mar 16, 2023 06:03 PM
Robot Policies in Asia
Mar 10, 2023 10:51 AM
Overview of ten Industrial Robot Company in China
Mar 10, 2023 12:59 AM
How Chinese SaaS Firms Survive Globalization
Mar 06, 2023 04:21 PM